<?xml version="1.0" encoding="UTF-8"?>
<snippetsTree>
 <snippets file="drug\PMC7239338\results\search\testTrace\results.xml">
  <result pre="other emerging viruses. EBOLA VIRUS DISEASE EVD is caused by" exact="infection" post="with a virus of the family Filoviridae, genus Ebolavirus."/>
  <result pre="of 2â€&quot;21Â days, symptomatic patients enter an acute phase of" exact="infection" post="during which they are highly contagious.14 Early symptoms include"/>
  <result pre="2014, the WHO established a list of drug candidates for" exact="testing" post="in patients with EVD.30 Among those candidates was favipiravir"/>
  <result pre="(Tâ€�705), an RNA polymerase inhibitor approved in Japan for the" exact="treatment" post="of noncomplicated influenza infections and in clinical development in"/>
  <result pre="Mauritius Island were infected 2Â days after the initiation of" exact="treatment" post="(preâ€�exposure prophylaxis). Although treated animals had a median peak"/>
  <result pre="exhibit a complex nonlinear kinetics in the early days of" exact="treatment" post="with, in addition, a progressive reduction in drug concentrations"/>
  <result pre="the decline in drug levels observed in the days following" exact="treatment" post="initiation (Figure 1). Interestingly, kenz was significantly larger in"/>
  <result pre="macaques from Mauritius Island using the same design (i.e., with" exact="treatment" post="starting 2Â days prior to infection and continuing for"/>
  <result pre="same design (i.e., with treatment starting 2Â days prior to" exact="infection" post="and continuing for 14Â days; i.e., 12Â days postinfection)."/>
  <result pre="with ascending doses of favipiravir. Left: Study design (note that" exact="treatment" post="is administered 2Â days prior to infection). Right: Survival"/>
  <result pre="standard model of viral dynamics The basic model of viral" exact="infection" post="in absence of treatment, called in the following the"/>
  <result pre="from a single infected cell at the beginning of the" exact="infection" post="and given by R 0 = p Î² s"/>
  <result pre=". Figure 3 Model structures used to described acute viral" exact="infection" post="dynamicsÂ (a) â€œTarget cell limitedâ€� model of viral dynamics"/>
  <result pre="instantaneous rate of death, h(t). Modified from ref. 69. Antiviral" exact="treatment" post="during chronic infection During chronic infection, such as HIV"/>
  <result pre="death, h(t). Modified from ref. 69. Antiviral treatment during chronic" exact="infection" post="During chronic infection, such as HIV or HCV,49, 50"/>
  <result pre="viral load levels, V, are roughly constant in absence of" exact="treatment" post="and reflect the equilibrium between the process of viral"/>
  <result pre="elimination by the immune response, is compensated by de novo" exact="infection" post="of target cells that constantly replenish the pool of"/>
  <result pre="the initiation of an antiviral drug may primarily block new" exact="infection" post="with an effectiveness Î·, or block viral production with"/>
  <result pre="Î·, or block viral production with an effectiveness Îµ. These" exact="treatment" post="effect parameters vary between 0 (no drug effect) and"/>
  <result pre="(full suppression). In chronic infection, the role of an antiviral" exact="treatment" post="is to reduce viral replication, making the few remaining"/>
  <result pre="and to support infection. Viral clearance can be achieved if" exact="treatment" post="effectiveness passes a threshold, called the â€œcritical efficacy,â€� and"/>
  <result pre="to be 7 on average, with large interindividual variation51; thus," exact="treatment" post="efficacy needs to be in the order of 90â€&quot;99%"/>
  <result pre="not taken into account in this model, such as the" exact="treatment" post="duration, the presence of viral reservoirs, and the barrier"/>
  <result pre="response and to achieve viral clearance in chronic infection. Antiviral" exact="treatment" post="during acute infection and the role of the innate"/>
  <result pre="achieve viral clearance in chronic infection. Antiviral treatment during acute" exact="infection" post="and the role of the innate immune response In"/>
  <result pre="such as influenza or EVD, the role of an antiviral" exact="treatment" post="is not so much to clear the infection, because"/>
  <result pre="a couple of days or weeks. Rather, using an antiviral" exact="treatment" post="may be relevant even if it does not reduce"/>
  <result pre="the innate and the adaptive immune response to acute viral" exact="infection" post="have been proposed (see for instance refs. 55, 56"/>
  <result pre="the action of the immune response results in limiting cell" exact="infection" post="(for instance via an interferon (IFN) response, see ref."/>
  <result pre="dynamic interaction between the host and the virus, an antiviral" exact="treatment" post="can be beneficial even if it does not abrogate"/>
  <result pre="is averted. This is illustrated in Figure 4, where a" exact="treatment" post="initiated at D0 with an effect of 50%, which"/>
  <result pre="shown (Figure 4 bottom). Figure 4 Effect of an antiviral" exact="treatment" post="on viral dynamics according to the timing of treatment"/>
  <result pre="antiviral treatment on viral dynamics according to the timing of" exact="treatment" post="initiation (left: day 0, middle: day 3; right: day"/>
  <result pre="cell limited model (Eq. 2) according to the timing of" exact="treatment" post="initiation. The following parameter values were used to generate"/>
  <result pre="limited model, q was set to 0. The timing of" exact="treatment" post="initiation is a key parameter in both models, with"/>
  <result pre="initiation is a key parameter in both models, with delayed" exact="treatment" post="intervention requiring higher efficacy to achieve a similar reduction"/>
  <result pre="a similar reduction in peak viremia. In our example, if" exact="treatment" post="is initiated at D5, the treatment efficacy Îµ will"/>
  <result pre="In our example, if treatment is initiated at D5, the" exact="treatment" post="efficacy Îµ will need to be &amp;gt;Â 90% to"/>
  <result pre="difficult in humans (due to the difficulty to identify viral" exact="infection" post="before symptoms occur) but also in animal models, due"/>
  <result pre="eradication, only asymptotically, and cannot address the question of optimal" exact="treatment" post="duration). A paradox of these models is that, in"/>
  <result pre="does not step in and all cells remain targets when" exact="treatment" post="is stopped. Because viral dynamic models are deterministic, it"/>
  <result pre="a large number of target cells are present. Thus, if" exact="treatment" post="is stopped, virus dynamics will be similar to an"/>
  <result pre="is stopped, virus dynamics will be similar to an acute" exact="infection" post="without any treatment. To address the question of treatment"/>
  <result pre="acute infection without any treatment. To address the question of" exact="treatment" post="duration needed to achieve cure, one would need to"/>
  <result pre="to an estimated R0 of 9, which suggests that a" exact="treatment" post="efficacy larger than 90% would be needed to block"/>
  <result pre="a high antiviral effectiveness of about 95%. In mice starting" exact="treatment" post="at D6 (i.e., 2Â days before peak viremia), the"/>
  <result pre="treatment at D6 (i.e., 2Â days before peak viremia), the" exact="treatment" post="period was sufficient to reduce the peak viremia by"/>
  <result pre="by 1.5 log. However, in mice treated at D8, the" exact="treatment" post="initiation was too late and the activity of favipiravir"/>
  <result pre="in Section â€œGeneral concepts on modeling viral dynamics and antiviral" exact="treatment" post="during an acute infectionâ€�, cannot be satisfactorily explained by"/>
  <result pre="(iv). Models assuming that proâ€�inflammatory cytokines increased cell refractoriness to" exact="infection" post="consistently provided the best description of the viral load"/>
  <result pre="and could reproduce both the cytokineâ€�mediated lymphopenia observed in early" exact="infection" post="and the rapid viral decline in NHPs after peak"/>
  <result pre="additional benefit for cell protection. Thus, in untreated animals, the" exact="infection" post="affects a significant proportion of the target cells, and"/>
  <result pre="in treated animals, favipiravir reduces viral production and slows the" exact="infection" post="progression. Hence, the number of infected cells and IFNÎ±"/>
  <result pre="predicted that this level would remain largely similar even if" exact="treatment" post="initiation is delayed up to D3, but not afterward"/>
  <result pre="predicted that 100% (resp. 70%) survival could be obtained if" exact="treatment" post="is initiated up to D4 (resp. D5), consistent with"/>
  <result pre="10Â mg/kg 3Â days after viral challenge (Figure 6).4 However," exact="treatment" post="given after D5 would not affect survival, regardless of"/>
  <result pre="model given in Figure 3c depending on the day of" exact="treatment" post="initiation, for various treatment potency. LESSONS FOR THE FUTURE"/>
  <result pre="3c depending on the day of treatment initiation, for various" exact="treatment" post="potency. LESSONS FOR THE FUTURE EVALUATION AND USE OF"/>
  <result pre="all doses considered, consistent with our results obtained for Ebola" exact="infection" post="in mice.80 Our analyses did not find a statistically"/>
  <result pre="7). Given that peak viremia occurred 2â€&quot;3Â days after subcutaneous" exact="infection" post="in this animal model, the window for treatment is"/>
  <result pre="after subcutaneous infection in this animal model, the window for" exact="treatment" post="is nonetheless narrow and the model predicted that treatment"/>
  <result pre="for treatment is nonetheless narrow and the model predicted that" exact="treatment" post="needs to be administered no later than day 1"/>
  <result pre="of plasma viremia occurs later, potentially allowing for later antiviral" exact="treatment" post="initiation. Furthermore, as favipiravir penetrates the sexual compartments and"/>
  <result pre="crosses the blood brain barrier,31 an important benefit of the" exact="treatment" post="may be to purge the reservoirs of the virus,"/>
  <result pre="Figure 7 Viral dynamic predictions in Zika infections. Left: Prophylactic" exact="treatment" post="assuming two different levels of drug halfâ€�maximal effective concentration"/>
  <result pre="of drug halfâ€�maximal effective concentration (EC50); right: effect of delayed" exact="treatment" post="initiations on Zika dynamics. This dosing regimen was also"/>
  <result pre="was also recently evaluated in an NHP model of Marburg" exact="infection" post="treated in prophylaxis. Interestingly, although the 6 untreated animals"/>
  <result pre="possible that the NHP models are more stringent and that" exact="treatment" post="initiation of a potent drug, closer to peak viremia,"/>
  <result pre="the time from symptom onset to admission in the Ebola" exact="treatment" post="centers was between 3 and 5Â days37, 86 when"/>
  <result pre="such as JIKI (favipiravir) or Prevail II (ZMapp),86 initiated antiviral" exact="treatment" post="close to the peak viremia and several days after"/>
  <result pre="their efficacy could remain largely contingent on the timing of" exact="treatment" post="initiation, and monoclonal antibodies remain uneasy to use in"/>
  <result pre="drugs. In spite of the difficulty to collect data in" exact="treatment" post="centers during epidemics, more modelers should be involved in"/>
  <result pre="the Western African EVD outbreak to propose an early oral" exact="treatment" post="to suspected cases, even before their transfer to care"/>
  <result pre="plasma viral dynamics in nonhuman primates provides insights into early" exact="infection" post="and antiviral strategies. Proc. Natl. Acad. Sci.114, 8847â€&quot;8852 (2017).28765371"/>
  <result pre="C.A., Hayden, F.G. &amp;amp; Perelson, A.S.Kinetics of influenza A virus" exact="infection" post="in humans. J. Virol.80, 7590â€&quot;7599 (2006).16840338 13Smith, A.M.et alKinetics"/>
  <result pre="novel Ebola virus expressing luciferase allows for rapid and quantitative" exact="testing" post="of antivirals. Antiviral Res.99, 207â€&quot;213 (2013).23751367 22Caballero, I.S.et alIn"/>
  <result pre="Antiviral Res.99, 207â€&quot;213 (2013).23751367 22Caballero, I.S.et alIn vivo Ebola virus" exact="infection" post="leads to a strong innate response in circulating immune"/>
  <result pre="C., Baize, S. &amp;amp; Leroy, E.M.Human fatal Zaire Ebola virus" exact="infection" post="is associated with an aberrant innate immunity and with"/>
  <result pre="virological, and biological parameters associated with outcomes of Ebola virus" exact="infection" post="in Macenta, Guinea. JCI Insight2, e88864 (2017).28352651 27Reynard, S.et"/>
  <result pre="JCI Insight4, pii: 125106 (2019). 28McElroy, A.K.et alHuman Ebola virus" exact="infection" post="results in substantial immune activation. Proc. Natl. Acad. Sci."/>
  <result pre="Organization . Categorization and prioritization of drugs for consideration for" exact="testing" post="or use in patients infected with Ebola. In: Ebola"/>
  <result pre="of the pharmacokinetic and pharmacodynamic properties of drugs considered for" exact="testing" post="in human efficacy trials. Clin. Pharmacokinet.55, 907â€&quot;923 (2016).26798032 32Japanese"/>
  <result pre="on the Deliberation Results (English version). &amp;lt;https://www.pmda.go.jp/files/000210319.pdf&amp;gt;. 33Oestereich, L.et alSuccessful" exact="treatment" post="of advanced Ebola virus infection with Tâ€�705 (favipiravir) in"/>
  <result pre="version). &amp;lt;https://www.pmda.go.jp/files/000210319.pdf&amp;gt;. 33Oestereich, L.et alSuccessful treatment of advanced Ebola virus" exact="infection" post="with Tâ€�705 (favipiravir) in a small animal model. Antiviral"/>
  <result pre="alPostâ€�exposure efficacy of oral Tâ€�705 (Favipiravir) against inhalational Ebola virus" exact="infection" post="in a mouse model. Antiviral Res.104, 153â€&quot;155 (2014).24462697 35MentrÃ©,"/>
  <result pre="for children with Ebola. Lancet385, 603â€&quot;604 (2015). 37Sissoko, D.et alExperimental" exact="treatment" post="with favipiravir for Ebola virus disease (the JIKI Trial):"/>
  <result pre="baseline case fatality ratio of Ebola virus disease and inform" exact="treatment" post="studies: a retrospective cohort study. PLoS Med.12, e1001908 (2015).26625118"/>
  <result pre="706â€&quot;713 (2010).20463660 52Whalley, S.A.et alKinetics of acute hepatitis B virus" exact="infection" post="in humans. J. Exp. Med.193, 847â€&quot;854 (2001).11283157 53Ribeiro, R.M.et"/>
  <result pre="infection. J. Virol.84, 6096â€&quot;6102 (2010).20357090 54Carrat, F.et alTime lines of" exact="infection" post="and disease in human influenza: a review of volunteer"/>
  <result pre="Theor. Biol.347, 63â€&quot;73 (2014).24440713 56Saenz, R.A.et alDynamics of influenza virus" exact="infection" post="and pathology. J. Virol.84, 3974â€&quot;3983 (2010).20130053 57Stetson, D.B. &amp;amp;"/>
  <result pre="Virol.16, 15â€&quot;23 (2016).26590692 59Smith, A.M. &amp;amp; Perelson, A.S.Influenza A virus" exact="infection" post="kinetics: quantitative data and models. Wiley Interdiscip. Rev. Syst."/>
  <result pre="e0158237 (2016).27367230 64Pawelek, K.A.et alModeling withinâ€�host dynamics of influenza virus" exact="infection" post="including immune responses. PLoS Comput. Biol.8, e1002588 (2012).22761567 65Pearson,"/>
  <result pre="Biol.21, R548â€&quot;R550 (2011).21783034 73Shi, C. &amp;amp; Pamer, E.G.Monocyte recruitment during" exact="infection" post="and inflammation. Nat. Rev. Immunol.11, 762â€&quot;774 (2011).21984070 74DesmÃ©e, S.,"/>
  <result pre="(2017).27148956 76Rosenke, K.et alUse of favipiravir to treat Lassa virus" exact="infection" post="in macaques. Emerg. Infect. Dis.24, 1696â€&quot;1699 (2018).29882740 77Westover, J.B.et"/>
  <result pre="viruses. Antiviral Res.126, 62â€&quot;68 (2016).26711718 78Raabe, V.N.et alFavipiravir and ribavirin" exact="treatment" post="of epidemiologically linked cases of Lassa fever. Clin. Infect."/>
  <result pre="Lancet386, 857â€&quot;866 (2015).26248676 91Marzi, A.et alVSVâ€�EBOV rapidly protects macaques against" exact="infection" post="with the 2014/15 Ebola virus outbreak strain. Science349, 739â€&quot;742"/>
 </snippets>
</snippetsTree>
